Navigation Links
VIA Pharmaceuticals to Present at 13th Annual IBC Life Sciences Drug Discovery & Development of Innovative Therapeutics World Congress
Date:8/1/2008

SAN FRANCISCO, Aug. 1 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that Rebecca A. Taub, MD, VIA's senior vice president of research and development, will present at the 13th Annual IBC Life Sciences Drug Discovery & Development of Innovative Therapeutics World Congress taking place August 4-7 in Boston, MA.

The presentation details are as follows:

Date/Time: Wednesday, August 6, 2008: 2:20-2:50 p.m. ET

Location: World Trade Center Boston & Seaport Hotel

Session: Translational Medicine IV: Case Studies of Translational

Approaches from Preclinical to Clinical Proof-of-Concept

Title: Innovative Clinical Trial and Biomarker Approaches To Demonstrate

the Role Of Leukotrienes and 5LO Inhibition in Atherosclerotic Disease

"VIA has taken an innovative approach in its design of Phase 2 clinical trials for VIA-2291, its lead compound," said Dr. Taub. "I am excited to share with conference participants our view on the value of innovative techniques in the design of critical clinical trials, particularly with regards to serum inflammatory biomarkers, analyses of atherosclerotic plaque tissue, and non-invasive imaging."

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease. VIA is building a pipeline of small-molecule drugs that target a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. The company's lead drug candidate, VIA-2291, is in multiple Phase 2 clinical studies in patients with cardiovascular disease. For more information, visit: http://www.viapharmaceuticals.com.


'/>"/>
SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Onyx Pharmaceuticals to Present at Bank of America 2008 Specialty Pharmaceuticals Conference
2. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
3. Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
4. Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP)
5. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
6. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
7. Sierra Neuropharmaceuticals Completes $21.5-Million Series A Funding Round
8. Anadys Pharmaceuticals Reports Second Quarter 2008 Financial Results and Highlights
9. Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
10. Poniard Pharmaceuticals Announces Upcoming Conference Participation
11. Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on August 5, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in clinical ... Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits ... tips, tools, and strategies for clinical researchers. , “The landscape of how patients ...
Breaking Biology Technology:
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
(Date:5/24/2016)... superior patient care by providing unparalleled technology to leaders of the medical imaging industry. ... recently added to the range of products distributed by Ampronix. Photo - ... ... ... ...
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
Breaking Biology News(10 mins):